Literature DB >> 31015162

Prognostic value of the texture analysis parameters of the initial computed tomographic scan for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.

Benjamin Vandendorpe1, Carole Durot2, Loïc Lebellec3, Marie-Cécile Le Deley4, Dienabou Sylla3, André-Michel Bimbai3, Kocéila Amroun5, Fabrice Ramiandrisoa1, Abel Cordoba6, Xavier Mirabel6, Christine Hoeffel2, David Pasquier6, Stéphanie Servagi-Vernat7.   

Abstract

BACKGROUND AND
PURPOSE: Baseline contrast-enhanced computed tomography (CT)-derived texture analysis in locally advanced rectal cancer could help offer the best personalized treatment. The purpose of this study was to determine the value of baseline-CT texture analysis in the prediction of downstaging in patients with locally advanced rectal cancer. PATIENTS AND METHODS: We retrospectively included all consecutive patients treated with neoadjuvant chemoradiation therapy (CRT) followed by surgery for locally advanced rectal cancer. Tumor texture analysis was performed on the baseline pre-CRT contrast-enhanced CT examination. Based on the selected model of downstaging with a penalized logistic regression in a training set, a radiomics score (Radscore) was calculated as a linear combination of selected features. A multivariable prognostic model that included Radscore and clinical factors was created.
RESULTS: Of the 121 patients included in the study, 109 patients (90%) had T3-T4 cancer and 99 (82%) had N+ cancer. A downstaging response was observed in 96 patients (79%). In the training set (79 patients), the best model (ELASTIC-NET method) reduced the 36 texture features to a combination of 6 features. The multivariate analysis retained the Radscore (odds ratio [OR] = 13.25; 95% confidence interval [95% CI], 4.06-71.64; p < 0.001) and age (OR = 1.10/1 year; 1.03-1.20; p = 0.008) as independent factors. In the test set, the area under the curve was estimated to be 0.70 (95% CI, 0.48-0.92).
CONCLUSION: This study presents a prognostic score for downstaging, from initial computed tomography-derived texture analysis in locally advanced rectal cancer, which may lead to a more personalized treatment for each patient.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Computed tomography; Neoadjuvant therapy; Prognostic value; Rectal cancer; Texture analysis

Mesh:

Year:  2019        PMID: 31015162     DOI: 10.1016/j.radonc.2019.03.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

Review 1.  Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer.

Authors:  Yun Qin; Li-Hua Zhu; Wei Zhao; Jun-Jie Wang; Hao Wang
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

2.  Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis.

Authors:  Toru Tochigi; Sophia C Kamran; Anushri Parakh; Yoshifumi Noda; Balaji Ganeshan; Lawrence S Blaszkowsky; David P Ryan; Jill N Allen; David L Berger; Jennifer Y Wo; Theodore S Hong; Avinash Kambadakone
Journal:  Eur Radiol       Date:  2021-10-13       Impact factor: 7.034

3.  External Validation of a Radiomics Model for the Prediction of Complete Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Anaïs Bordron; Emmanuel Rio; Bogdan Badic; Omar Miranda; Olivier Pradier; Mathieu Hatt; Dimitris Visvikis; François Lucia; Ulrike Schick; Vincent Bourbonne
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

4.  Combining Radiomics and Blood Test Biomarkers to Predict the Response of Locally Advanced Rectal Cancer to Chemoradiation.

Authors:  Seung Hyuck Jeon; Changhoon Song; Eui Kyu Chie; Bohyoung Kim; Young Hoon Kim; Won Chang; Yoon Jin Lee; Joo-Hyun Chung; Jin Beom Chung; Keun-Wook Lee; Sung-Bum Kang; Jae-Sung Kim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

5.  Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.

Authors:  Yue Li; Jun Liu; Hong-Xuan Li; Xu-Wei Cai; Zhi-Gang Li; Xiao-Dan Ye; Hao-Hua Teng; Xiao-Long Fu; Wen Yu
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

6.  Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images.

Authors:  Xu Chang; Xing Guo; Xiaole Li; Xiaowei Han; Xiaoxiao Li; Xiaoyan Liu; Jialiang Ren
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

7.  Radiomics of Patients with Locally Advanced Rectal Cancer: Effect of Preprocessing on Features Estimation from Computed Tomography Imaging.

Authors:  Stefania Linsalata; Rita Borgheresi; Daniela Marfisi; Patrizio Barca; Aldo Sainato; Fabiola Paiar; Emanuele Neri; Antonio Claudio Traino; Marco Giannelli
Journal:  Biomed Res Int       Date:  2022-03-20       Impact factor: 3.411

8.  Simulation CT-based radiomics for prediction of response after neoadjuvant chemo-radiotherapy in patients with locally advanced rectal cancer.

Authors:  Pierluigi Bonomo; Jairo Socarras Fernandez; Daniela Thorwarth; Marta Casati; Lorenzo Livi; Daniel Zips; Cihan Gani
Journal:  Radiat Oncol       Date:  2022-04-28       Impact factor: 4.309

9.  Clinical utility of radiomics at baseline rectal MRI to predict complete response of rectal cancer after chemoradiation therapy.

Authors:  Iva Petkovska; Florent Tixier; Eduardo J Ortiz; Jennifer S Golia Pernicka; Viktoriya Paroder; David D Bates; Natally Horvat; James Fuqua; Juliana Schilsky; Marc J Gollub; Julio Garcia-Aguilar; Harini Veeraraghavan
Journal:  Abdom Radiol (NY)       Date:  2020-11

10.  Radiomics Model Based on Non-Contrast CT Shows No Predictive Power for Complete Pathological Response in Locally Advanced Rectal Cancer.

Authors:  Gordian Hamerla; Hans-Jonas Meyer; Peter Hambsch; Ulrich Wolf; Thomas Kuhnt; Karl-Titus Hoffmann; Alexey Surov
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.